stockrowNervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
Follow NGEN
Alert me
NervGen Pharma Corp. (NGEN) Dividend Safety Score
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| NGEN NervGen Pharma Corp. | — |
| MGNX MacroGenics, Inc. compare | — |
| ADAG Adagene Inc. Sponsored ADR compare | — |
| ANTX AN2 Therapeutics, Inc. compare | — |
| VRXA Veraxa Biotech AG compare | — |
| SION Sionna Therapeutics, Inc. compare | — |
| STRO Sutro Biopharma, Inc. compare | — |
| MSLE Satellos Bioscience Inc. compare | — |
| INO Inovio Pharmaceuticals, Inc. compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings